Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 1, 2026

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

9.8K

[Molecular lymph node staging in prostate and bladder cancer].

M M Heck1, M Retz, R Nawroth

  • 1Klinik und Poliklinik für Urologie, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Deutschland, m.heck@lrz.tum.de.

Der Urologe. Ausg. A
|March 28, 2014
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial.

ESMO open·2024
Same author

[German expert consensus on programmed cell death ligand 1 (PD-L1) testing in perioperative systemic therapy of muscle invasive bladder cancer].

Urologie (Heidelberg, Germany)·2024
Same author

[Value of immunotherapy in the perioperative treatment of localized muscle invasive bladder cancer].

Urologie (Heidelberg, Germany)·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
See all related articles

Molecular lymph node analysis can detect hidden cancer spread in patients with negative lymph nodes after prostate or bladder cancer surgery. This may improve risk assessment and predict tumor recurrence more accurately.

Area of Science:

  • Oncology
  • Pathology
  • Molecular Biology

Context:

  • Positive lymph node status is a key predictor of cancer recurrence and mortality after radical prostatectomy (prostate cancer) or radical cystectomy (bladder cancer).
  • A significant number of patients with histopathologically negative lymph nodes experience tumor recurrence, suggesting undetected metastatic spread.
  • Current histopathologic examination may not detect minimal or microscopic metastatic disease in lymph nodes.

Purpose:

  • To investigate the potential of molecular lymph node analysis for detecting lymph node metastases.
  • To enhance the prognostic accuracy for patients with histopathologically negative lymph nodes.
  • To identify a more sensitive method for risk stratification in prostate and bladder cancer patients.

Summary:

More Related Videos

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

14.6K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

10.8K

Related Experiment Videos

Last Updated: May 1, 2026

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

9.8K
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

14.6K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

10.8K
  • Molecular lymph node analysis offers a highly sensitive method for detecting lymph node metastases that are missed by conventional histopathology.
  • This technique can identify occult tumor spread in patients with negative lymph nodes, who are at risk for recurrence.
  • The findings suggest molecular analysis can improve the prognostic stratification of patients undergoing radical prostatectomy or cystectomy.

Impact:

  • Improved early detection of cancer metastasis in lymph nodes.
  • More accurate prediction of tumor recurrence and patient outcomes.
  • Enhanced clinical decision-making for adjuvant therapy in node-negative cancer patients.